REGENXBIO Inc. presented new data evaluating ABBV-RGX-314, an investigational AAV Therapeutic developed with AbbVie, for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) at the American Academy of Ophthalmology (AAO) 2024 annual meeting.
ABBV-RGX-314 for Wet AMD
Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates, presented the first results of a fellow eye bilateral dosing study of subretinal ABBV-RGX-314 in patients with bilateral wet AMD on Saturday, October 19, 2024. The presentation, titled "Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study," highlighted the potential of this one-time gene therapy.
ABBV-RGX-314 for Diabetic Retinopathy
Dr. Khanani also presented data from a Phase 2 dose-escalation study evaluating suprachoroidal delivery of ABBV-RGX-314 gene therapy for DR on Monday, October 21, 2024. This presentation, titled "A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for DR," explored a different delivery method for treating DR.
Long-Term Follow-Up in nAMD
Philip P. Storey, M.D., Austin Retina Associates, presented long-term follow-up study results from the Phase I/IIa ABBV-RGX-314 subretinal delivery gene therapy program in nAMD on Monday, October 21, 2024. The presentation, titled "Long-Term Follow-Up Study Results from the Investigational Phase I/IIa ABBV-RGX-314 Subretinal Delivery Gene Therapy Program in nAMD," provided insights into the durability of the gene therapy's effects.
REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for mucopolysaccharidosis type II (MPS II).
